CSRxP: DISAPPOINTED CONGRESS DID NOT PASS CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS TO HOLD BIG PHARMA ACCOUNTABLE, INCREASE COMPETITION
Campaign Will Work with Lawmakers in the New Congress and the New… Read More
Campaign Will Work with Lawmakers in the New Congress and the New… Read More
Lawmakers Should Pass Bipartisan, Market-Based Solutions to Crack Down on… Read More
Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent… Read More
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
AARP Urges Lawmakers to Pass Cornyn-Blumenthal On Friday, AARP urged lawmakers… Read More
ICER Analysis Highlights Big Pharma Price Hikes Outpacing Inflation on Brand… Read More
Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse… Read More
Big Pharma Giant Proceeds With Strategy to Block Competition, Add More Patents… Read More
Congress Should Not Further Consider Misguided Proposal That Would Enable More… Read More
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
Brand Name Manufacturers Continue to Charge U.S. Patients Highest Prices in… Read More
Gilead CEO Touts Success of Company’s Patent Playbook on HIV Portfolio That… Read More